Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review.
Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review.
复制标题
美国阿尔茨海默病神经影像学研究中种族/民族代表性的量化：一项系统综述
DOI：
10.1038/s43856-023-00333-6
复制
发表时间：
2023-07-25
期刊：
影响因子：
--
通讯作者：
Han, S Duke
中科院分区：
文献类型：
--
作者：
Lim, Aaron C;Barnes, Lisa L;Weissberger, Gali H;Lamar, Melissa;Nguyen, Annie L;Fenton, Laura;Herrera, Jennifer;Han, S Duke
种族和少数民族群体患阿尔茨海默病（AD）的风险不成比例，但在美国的AD神经影像学研究中没有充分招募。这一点很重要，因为样本组成影响发现的普遍性、生物标志物临界值和治疗效果。没有研究量化了AD文献中种族/民族代表性的广度。该综述确定了以美国为基础的AD神经影像学研究样本的中位种族/民族组成，这些样本可作为PubMed上的免费全文文章提供。分析了两种类型的已发表研究：直接报告人种/种族数据的研究（即，直接研究），以及不报告人种/种族但使用来自确实报告该信息的队列研究/数据库的数据的研究（即，间接研究）。直接研究（n = 719）的中位代表性为88.9%的白色或87.4%的非西班牙裔白色、7.3%的黑人/非裔美国人和3.4%的西班牙裔/拉丁裔种族，0%的亚裔美国人、夏威夷原住民/太平洋岛民和美国印第安人/阿拉斯加原住民、多种族和其他种族参与者。间接研究（n = 1745）来源的队列研究/数据库（n = 44）更加多样化，中位代表性为84.2%白色、83.7%非西班牙裔白色、11.6%黑人/非裔美国人、4.7%西班牙裔/拉丁裔和1.75%亚裔美国人受试者。值得注意的是，94%的间接研究来自10个队列研究/数据库。使用1994-2017年和2018-2022年出版年份的中位数对两个时间段进行比较，表明样本多样性最近有所改善，特别是黑人/非裔美国人参与者（1994-2017年为3.39%，2018-2022年为8.29%）。相对于人口普查数据，所有少数群体的代表性仍然不足，特别是西班牙裔/拉丁裔和亚裔美国人。AD神经影像学文献将受益于少数民族/种族代表性招募的增加。需要更加透明地报告种族/族裔数据。在美国，一些种族和少数民族的成员比白色人更容易患阿尔茨海默病。然而，它们通常不包括在阿尔茨海默病的研究中。我们研究了在美国发表的描述阿尔茨海默病研究的论文中评估的人的种族/民族组成，这些研究使用了大脑图像。我们发现，所有种族/少数民族群体在阿尔茨海默病研究中的代表性不足，尤其是西班牙裔/拉丁裔和亚裔美国人。重要的是，研究包括所有人群的代表，这既是为了这些人群的健康，也是为了提高所有人对阿尔茨海默病的认识。这些研究还应有助于理解和解决阿尔茨海默病诊断和治疗中的种族/民族差异。Lim等人对美国阿尔茨海默病患者的神经影像学研究中的种族/民族代表性进行了系统综述。虽然近年来样本多样性有所增加，但美国的少数群体仍然代表性不足，需要更透明的种族/族裔数据报告。
Racial and ethnic minoritized groups are disproportionately at risk for Alzheimer’s Disease (AD), but are not sufficiently recruited in AD neuroimaging research in the United States. This is important as sample composition impacts generalizability of findings, biomarker cutoffs, and treatment effects. No studies have quantified the breadth of race/ethnicity representation in the AD literature. This review identified median race/ethnicity composition of AD neuroimaging US-based research samples available as free full-text articles on PubMed. Two types of published studies were analyzed: studies that directly report race/ethnicity data (i.e., direct studies), and studies that do not report race/ethnicity but used data from a cohort study/database that does report this information (i.e., indirect studies). Direct studies (n = 719) have median representation of 88.9% white or 87.4% Non-Hispanic white, 7.3% Black/African American, and 3.4% Hispanic/Latino ethnicity, with 0% Asian American, Native Hawaiian/Pacific Islander, and American Indian/Alaska Native, Multiracial, and Other Race participants. Cohort studies/databases (n = 44) from which indirect studies (n = 1745) derived are more diverse, with median representation of 84.2% white, 83.7% Non-Hispanic white, 11.6% Black/African American, 4.7% Hispanic/Latino, and 1.75% Asian American participants. Notably, 94% of indirect studies derive from just 10 cohort studies/databases. Comparisons of two time periods using a median split for publication year, 1994–2017 and 2018–2022, indicate that sample diversity has improved recently, particularly for Black/African American participants (3.39% from 1994–2017 and 8.29% from 2018-2022). There is still underrepresentation of all minoritized groups relative to Census data, especially for Hispanic/Latino and Asian American individuals. The AD neuroimaging literature will benefit from increased representative recruitment of ethnic/racial minorities. More transparent reporting of race/ethnicity data is needed. Members of some racial and ethnic minority groups in the USA are more likely to develop Alzheimer’s Disease than white people. However, they are often not included in research studies of Alzheimer’s Disease. We looked at the race/ethnicity composition of people evaluated in papers published describing Alzheimer’s Disease research studies based in the USA that used images of the brain. We found that all racial/ethnic minority groups were underrepresented in Alzheimer’s Disease research studies, especially Hispanic/Latino and Asian American individuals. It is important that studies include representatives of all populations both for the health of those populations and improved understanding of Alzheimer’s Disease in all people. Such studies should also improve efforts to understand and address racial/ethnic disparities in Alzheimer’s Disease diagnosis and treatment. Lim et al. provide a systematic review of the race/ethnicity representation in USA based neuroimaging studies of those with Alzheimer’s Disease. Whilst sample diversity has increased in recent years, minoritized groups in the USA remain underrepresented and more transparent reporting of race/ethnicity data is needed.
影响因子：
5.5
作者：
Barbash S
通讯作者：
Barbash S